Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effects of low-dose recombinant human erythropoietin treatment on cognitive performance

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Reduction in maternal mortality in Denmark over three decades

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. An audit of 70 maternal deaths

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Criteria-based dispatch of emergency medical services in non-traumatic subarachnoid haemorrhage

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Characteristics of patients reporting symptoms by open-ended questions in specialist palliative care

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Amitriptyline accumulation in tissues after coated activated charcoal hemoperfusion-a randomized controlled animal poisoning model

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Advanced Electrocardiogram Analysis in the Amitriptyline-poisoned Pig Treated with Activated Charcoal Haemoperfusion

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Citrate, a Ubiquitous Key Metabolite with Regulatory Function in the CNS

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Søren Lundgaard Viuff
  • Ulla Plenge
  • Bo Belhage
  • Robert Boushel
  • Thomas Koester
View graph of relations

INTRODUCTION: High-dose recombinant human erythropoietin (rhEpo) has been shown to improve cognitive performance in both healthy volunteers and in patients suffering from diseases affecting the brain. The aim of this study was to examine whether administration of low-dose and even micro-dose rhEpo improves cognitive performance in healthy volunteers.

METHODS: We enrolled 25 healthy volunteers in a double-blind, randomised, placebo-controlled study to receive either low-dose rhEpo (n = 8, 60 IU/kg/week), micro-dose rhEpo (n = 9, 20 IU/kg/week), or saline (n = 8) for four weeks. Two cognitive performance-tests, the Raven Standard Progressive Matrices (Raven) and the Number Finder (NUFI), were performed during the first and last day of the study period. Semi-structured interviews were conducted weekly and were coded according to a scale.

RESULTS: Subjects receiving micro-dose rhEpo improved significantly measured by the Raven score (p = 0.04), and subjects receiving low-dose rhEpo treatment improved significantly measured by the NUFI score (p = 0.047), whereas no improvement was found in experienced cognitive performance in any of the groups. We found no significant difference in either Raven, NUFI or self-reported results between the groups.

CONCLUSIONS: In this small study, we found no significant effect of low-dose or micro-dose rhEpo on visual attention, cognitive performance in complex cognitive tasks or self-experienced cognitive performance compared with placebo.

FUNDING: The Aase and Ejnar Danielsen's Foundation. Danish Ministry of Science, Innovation and Higher Education.

TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03093506.

Original languageEnglish
JournalDanish Medical Bulletin (Online)
Volume64
Issue number9
ISSN1603-9629
Publication statusPublished - Sep 2017

    Research areas

  • Journal Article

ID: 52645460